Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 05:57:59 +0200Wed, 05 Jun 2024 16:25:00 +0200Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 55, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/reyatazHuman medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 55, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/reyatazWed, 05 Jun 2024 16:25:00 +0200Human medicineSummary of opinion: Reyataz, 25/04/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/reyatazSummary of opinion: Reyataz, 25/04/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/reyatazFri, 26 Apr 2024 12:00:00 +0200Human medicineReyataz : EPAR - Summary for the publichttps://www.ema.europa.eu/system/files/documents/overview/wc500056381_en.pdfReyataz : EPAR - Summary for the publichttps://www.ema.europa.eu/system/files/documents/overview/wc500056381_en.pdfWed, 28 Sep 2016 02:00:00 +0200Human medicine